Trials / Completed
CompletedNCT00545090
ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 561 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Female
- Age
- 85 Years
- Healthy volunteers
- Not accepted
Summary
This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study. All patients completing 6 months in ML19930 will continue to receive Bonviva (150mg po, monthly) for an additional 6 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ibandronate [Bonviva/Boniva] | 150mg po monthly for 6 months |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2007-10-17
- Last updated
- 2016-11-10
Locations
17 sites across 5 countries: Hong Kong, Indonesia, Philippines, Taiwan, Thailand
Source: ClinicalTrials.gov record NCT00545090. Inclusion in this directory is not an endorsement.